(NASDAQ: LVTX) Lava Therapeutics Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.75%.
Lava Therapeutics Nv's earnings in 2024 is -$26,574,725.On average, 3 Wall Street analysts forecast LVTX's earnings for 2024 to be -$33,660,572, with the lowest LVTX earnings forecast at -$37,605,170, and the highest LVTX earnings forecast at -$31,556,786. On average, 3 Wall Street analysts forecast LVTX's earnings for 2025 to be -$41,636,550, with the lowest LVTX earnings forecast at -$43,653,555, and the highest LVTX earnings forecast at -$38,657,063.
In 2026, LVTX is forecast to generate -$50,096,398 in earnings, with the lowest earnings forecast at -$58,906,001 and the highest earnings forecast at -$41,286,796.